Research programme: TNF-alpha antagonists - Gryphon TherapeuticsAlternative Names: D-TNF-α; D-TNF-α therapy research programme - Gryphon Therapeutics; Rheumatoid arthritis therapy research programme - Gryphon Therapeutics
Latest Information Update: 07 Mar 2011
At a glance
- Originator Gryphon Therapeutics
- Class Peptides
- Mechanism of Action Tumour necrosis factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 14 Jun 2004 Preclinical trials in Rheumatoid arthritis in USA (unspecified route)